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LETTER TO THE EDITOR
Adoptive tumour immunotherapy using human CD4+ T-cells
Sir - We read with interest the article by Nakamura et al.
(Br. J. Cancer (1992) 66, 20-26) describing the generation of
large numbers of CD4+CD45RO+ helper/killer T-cells for
potential use in adoptive tumour immunotherapy. It is these
cells that form the basis for autolymphocyte therapy (ALT).
As previously reported, ALT is adoptive tumour immuno-
therapy based upon the infusion ofCD4+CD45RO+ (memory)
T-cells that are activated ex vivo by low doses of the mito-
genic monoclonal antibody OKT3, in combination with a
previously prepared mixture of autologous cytokines (Celis et
al., 1991). We have demonstrated that ex vivo activation of
murine splenocytes results in the generation of tumour-
specific T-cells with a memory phenotype (Osband et al.,
1989). In addition, ex vivo depletion of CD45RO+ T-cells
from the autolymphocyte preparation markedly impairs ex
vivo lysis of autologous tumour targets (Gold et al., 1993).
Monthly infusions of autolymphocytes and daily oral cime-
tidine has been shown to be active in patients with metastatic
renal cell cancer (Osband et al., 1990; Lavin et al., 1992).
Similar to ALT, the cells generated by the methodology of
Nakamura et al. were made up mostly of the CD45RO+
subset of CD4+ T-cells.
There are however, two important distinctions and issues
that need to be addressed regarding both autolymphocytes
and the CD4+ helper/killer T-cells of the report by
Nakamura et al. The first is that autolymphocytes are deriv-
ed ex vivo from activation of unseparated peripheral blood
lymphocytes (PBL). As stated, it has been shown that non-
specific ex vivo activation of murine splenocytes results in the
generation of autolymphocytes that are tumour-specific
(Osband et al., 1989) and that high levels of interleukin
(IL)-1 rather than IL-2 in human ex vivo cell cultures cor-
relate with improved clinical efficacy (Osband et al., 1990;
Lavin et al., 1992). Therefore, it may not be necessary to
separate the CD4+ T-cell subset from PBL, and in fact may
be clinically advantageous and physiologic to activate and
then infuse memory T-cells as part of a heterogeneous cell
population for adoptive tumour immunotherapy (Panzer et
al., 1990). The second distinction involves the actual number
of cells to be infused. A commonly held belief in adoptive
tumour immunotherapy is that 'more is better'. That is, the
greater number of cells that one wishes to infuse, the better
for the patient. However, this may not be the case as it has
been demonstrated with ALT that more cells are not neces-
sarily better (Ross & Osband, 1989). Indeed, patients who
receive autolymphocytes above a certain threshold value may
actually do worse than those receiving less cells. It is possible
that a large number of autolymphocytes or CD4+ helper/
killer T-cells may cause an 'anti-idiotypic' reaction with con-
commitant generation of suppressor cells to down-regulate
the anti-tumour response. In addition, if the CD4+ T-cell
population is indeed the orchestrator of the anti-tumour
response, then a small number of cells may be all that is
required to initiate effective therapy. In summary while the
report by Nakamura et al. re-enforces the use of CD4+
T-cells in adoptive tumour immunotherapy, it may not be
necessary to separate the CD4+ T-cells from PBL or require
large numbers of cells for an effective anti-tumour response.
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